Related Experiment Video
Updated: May 13, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Do BRAF inhibitors select for populations with different disease progression kinetics?
Paolo Antonio Ascierto1, Ester Simeone, Antonio Maria Grimaldi
1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Department of Melanoma, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. paolo.ascierto@gmail.com
Journal of Translational Medicine
|March 19, 2013
Summary
Metastatic melanoma patients failing BRAF inhibitors may progress rapidly, potentially reducing ipilimumab benefit. Identifying fast vs. slow progressors is key for optimal sequential therapy in melanoma treatment.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Ipilimumab (anti-CTLA-4 antibody) improves survival in metastatic melanoma.
- Rapid disease progression observed in patients after BRAF inhibitor failure.
- Potential for reduced ipilimumab efficacy in this subgroup.
Purpose of the Study:
- To investigate the impact of prior BRAF inhibitor treatment on ipilimumab efficacy.
- To explore the identification of fast and slow progressing patient populations.
- To guide sequential therapy decisions in metastatic melanoma.
Main Methods:
- Analysis of patient outcomes based on prior treatment history.
- Evaluation of disease progression rates.
- Exploration of baseline risk factors for treatment selection.
Main Results:
- Preliminary data indicate faster progression in patients failing BRAF inhibitors.
- Potential differential benefit from ipilimumab based on prior BRAF inhibitor treatment.
- Need for further research to define optimal treatment sequencing.
Conclusions:
- Sequential therapy for metastatic melanoma requires careful consideration of prior treatments.
- Identifying predictors of response is crucial for guiding BRAF inhibitor vs. ipilimumab sequencing.
- Further research is needed to optimize treatment strategies for melanoma patients.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...